Baseline FIB-4 Does Not Modify Efpeglenatide’s Cardiovascular Benefit in Type 2 Diabetes (AMPLITUDE-O Exploratory Analysis)
Exploratory analysis of AMPLITUDE-O finds baseline FIB-4 score is not associated with cardiovascular outcomes and does not modify efpeglenatide's effect in high-risk type 2 diabetes. PICO summary and expert commentary.
